Objective. The objective of this study was to evaluate a cost-effectiveness strategy of bevacizumab in a subset of high-risk advanced ovarian cancer patients with survival benefit. Methods. A subset analysis of the International Collaboration on Ovarian Neoplasms 7 trial showed that additions of bevacizumab (B) and maintenance bevacizumab (mB) to paclitaxel (P) and carboplatin (C) improved the overall survival (OS) of high-risk advanced cancer patients. Actual and estimated costs of treatment were determined from Medicare payment. Incremental cost-effectiveness ratio per life-year saved was established. Results. The estimated cost of PC is 535percycle;PCB+mB(7.5mg/kg)is 3,760 per cycle for the first 6 cycles and then 3,225percyclefor12mBcycles.Of465high-riskstageIIIC(>1cmresidual)orstageIVpatients,thepreviouslyreportedOSafterPCwas28.8monthsversus36.6monthsinthosewhounderwentPCB+mB.Withanestimated8-monthimprovementinOS,theincrementalcost-effectivenessratioofBwas 167,771 per life-year saved. Conclusion. In this clinically relevant subset of women with high-risk advanced ovarian cancer with overall survival benefit after bevacizumab, our economic model suggests that the incremental cost of bevacizumab was approximately 170,000.